These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 87616)

  • 21. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sideroachrestic anemia with iron loading: treatment with desferrioxamine.
    Zoller WG; Hehlmann R
    Klin Wochenschr; 1986 May; 64(9):417-22. PubMed ID: 3713111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.
    Breithaupt H; Heckers H; Pralle H; Guttmann W; Bleyl H; Graef V; Jundt G
    Blut; 1986 Apr; 52(4):211-9. PubMed ID: 3634632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F; Mautone A; Cavallo L; Altomare M; Montagna O; Dell'Edera L
    Acta Haematol; 1981; 66(2):96-101. PubMed ID: 6794319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
    Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
    [No Abstract]   [Full Text] [Related]  

  • 34. [Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes].
    González FA; Arrizabalaga B; Villegas A; Alonso D; Castro M; Remacha A; del Arco A; Martín Núñez G;
    Med Clin (Barc); 2005 May; 124(17):645-7. PubMed ID: 15882510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
    Hehlmann R; Schmitz H; Krüger K
    Int J Cardiol; 1984 Jun; 5(6):749-53. PubMed ID: 6235195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME; Matthews RN; Alison JF; Menahem S; Mitvalsky J; Byrt E; Harper RW
    Aust N Z J Med; 1993 Dec; 23(6):656-61. PubMed ID: 8141693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.